CANADA LIFE ASSURANCE Co Purchases 1,311 Shares of Amgen Inc. (NASDAQ:AMGN)

CANADA LIFE ASSURANCE Co boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,931 shares of the medical research company’s stock after acquiring an additional 1,311 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in Amgen were worth $14,241,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AMGN. BOK Financial Private Wealth Inc. acquired a new stake in Amgen in the 4th quarter valued at $29,000. United Community Bank acquired a new stake in Amgen in the 4th quarter valued at $29,000. Horizon Financial Services LLC acquired a new stake in Amgen in the 1st quarter valued at $28,000. Planned Solutions Inc. acquired a new stake in Amgen in the 4th quarter valued at $30,000. Finally, Delos Wealth Advisors LLC increased its stake in Amgen by 2,500.0% in the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.69% of the stock is owned by company insiders.

Amgen Trading Down 0.7 %

Shares of NASDAQ:AMGN traded down $2.37 during midday trading on Thursday, reaching $333.24. The company’s stock had a trading volume of 1,453,541 shares, compared to its average volume of 2,662,319. The firm has a market capitalization of $178.76 billion, a price-to-earnings ratio of 47.94, a PEG ratio of 2.77 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The firm has a 50 day moving average price of $313.12 and a two-hundred day moving average price of $296.93. Amgen Inc. has a fifty-two week low of $228.21 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm’s revenue was up 22.0% compared to the same quarter last year. During the same period in the previous year, the business earned $3.98 EPS. As a group, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AMGN. Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $230.00 to $300.00 in a report on Friday, May 3rd. Raymond James assumed coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Argus upped their price target on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, TD Cowen decreased their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $312.63.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.